AriBio at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

AriBio takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on running a global phase 3 trial and building an oral drug franchise for Alzheimer's disease and related dementias. Its work includes an AI tool for clinical operations and data reconciliation.

Organization	CTAD 2026 Attendance
AriBio Seongnam, South Korea
aribiogroup.com Biotech Korean biotech developing AR1001 (mirodenafil), an oral PDE5 inhibitor, in the Phase 3 POLARIS-AD trial in early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer’s Disease Trial (P135) Digital assessment and AI · Trial design and endpoints Poster AriBio: Building an Oral Therapeutic Franchise Across Alzheimer’s Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005 (P515) Other mechanisms and targets

Organization

CTAD 2026 Attendance

AriBio

Seongnam, South Korea

aribiogroup.com

Biotech

Korean biotech developing AR1001 (mirodenafil), an oral PDE5 inhibitor, in the Phase 3 POLARIS-AD trial in early Alzheimer's disease.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer’s Disease Trial (P135)

Digital assessment and AI · Trial design and endpoints

Poster

AriBio: Building an Oral Therapeutic Franchise Across Alzheimer’s Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005 (P515)

Other mechanisms and targets

Instantly find 20 buyers from AriBio

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction